BioArctic (BRCTF) announced that it has entered into a global exclusive license agreement with Bristol Myers Squibb (BMY) for BioArctic’s PyroGlutamate-amyloid-beta antibody program, including BAN1503 and BAN2803, whereof the latter includes BioArctic’s BrainTransporter technology. As part of the agreement, BioArctic will receive a $100M upfront payment and up to $1.25B in milestone payments. BioArctic is also entitled to tiered low double-digit royalties on global product sales. Under the agreement, Bristol Myers Squibb will become solely responsible for the development and any subsequent commercialization of BAN1503 and BAN2803 and related products worldwide. BioArctic will receive a $100M upfront payment and up to $1.25B in development, regulatory and commercial milestones, as well as tiered royalties on global product sales. BioArctic will retain an option to co-commercialize the products in the Nordic region. The agreement is subject to filing and clearance under the U.S. Antitrust legislation. BioArctic’s PyroGlu-Ass antibody program consists of novel antibodies targeting a specific truncated, pyroglutamate modified form of amyloid-beta. Monomers of PyroGlu-Ass are highly prone to aggregate, leading to the formation of harmful aggregates which cause debilitating cognitive and other symptoms in Alzheimer’s disease. The agreement includes both the BAN1503 and BAN2803 antibodies. BAN2803 includes BioArctic’s BrainTransporter technology. Brain uptake of biotherapeutics such as antibodies and enzymes is severely limited by the blood brain barrier primarily due to their size. Active transport across the BBB, using one of the body’s own delivery mechanisms, aims to enable better drug uptake into the brain. The BrainTransporter technology utilizes the transferrin receptor, a protein facilitating transport across the BBB, to optimize brain delivery.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on BMY:
- Bristol Myers added to Analyst Focus List at JPMorgan
- Cytokinetics price target raised to $82 from $80 at RBC Capital
- Honeywell still exploring alternatives, Capri weighs Versace sale: Morning Buzz
- Netflix, MongoDB downgraded: Wall Street’s top analyst calls
- Bristol Myers upgraded to Buy at Jefferies on new launch momentum, pipeline
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
